Cullinan Oncology Inc (NASDAQ:CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology treatments, has reported an insider sell according to a recent SEC filing. Chief Business Officer Corrine Savill sold 40,000 shares of the company on January 23, 2024. The transaction was executed at an average price of $12.31 per share, resulting in a total value of $492,400.Over the past year, the insider has engaged in the sale of 40,000 shares and has not made any purchases of the company's stock. The recent transaction reflects the only activity by the insider in the past twelve months.The insider transaction history for Cullinan Oncology Inc shows a pattern of insider sales with 39 recorded over the past year and no insider buys during the same period.

On the day of the insider's recent sale, shares of Cullinan Oncology Inc were trading at $12.31, giving the company a market capitalization of $534.758 million.For more detailed information on insider transactions at Cullinan Oncology Inc, interested parties can refer to the SEC Filing.

• Warning! GuruFocus has detected 3 Warning Sign with CGEM.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.